NEW YORK (GenomeWeb) – Qiagen said on Tuesday that it has received CE-IVD marking for its Therascreen PITX2 RGQ PCR kit and launched the assay in Europe.

The new kit is a methylation assay intended to help predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. It runs on Qiagen's Rotor-Gene Q MDx real-time thermal cycler and can easily be adopted by customers already running Therascreen assays on the company's QIAsymphony automation platform.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.

In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.